Patents by Inventor Devin Swanson

Devin Swanson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9586962
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: March 7, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael A. Letavic, Dale A. Rudolph, Brad M. Savall, Brock T. Shireman, Devin Swanson
  • Publication number: 20140171430
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Application
    Filed: April 20, 2012
    Publication date: June 19, 2014
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Michael A. Letavic, Rudolph A. Dale, Brad M. Savall, Brock T. Shireman, Devin Swanson
  • Publication number: 20080056991
    Abstract: Substituted piperazinyl and diazepanyl benzamides and benzthioamides of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.
    Type: Application
    Filed: October 30, 2007
    Publication date: March 6, 2008
    Inventors: Richard Apodaca, Jill Jablonowski, Kiew Ly, Chandravadan Shah, Devin Swanson, Wei Xiao
  • Publication number: 20070100141
    Abstract: The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; sleep/wake disorders; cardiovascular disease; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.
    Type: Application
    Filed: October 27, 2006
    Publication date: May 3, 2007
    Inventors: Pascal Bonaventure, Nicholas Carruthers, Wenying Chai, Curt Dvorak, Jill Jablonowski, Dale Rudolph, Mark Seierstad, Chandravadan Shah, Devin Swanson, Victoria Wong
  • Publication number: 20050222129
    Abstract: Certain non-imidazole heterocyclic compounds are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.
    Type: Application
    Filed: March 31, 2005
    Publication date: October 6, 2005
    Inventors: Nicholas Carruthers, Chandravadan Shah, Devin Swanson
  • Publication number: 20050222151
    Abstract: Certain non-imidazole heterocyclic compounds are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.
    Type: Application
    Filed: March 31, 2005
    Publication date: October 6, 2005
    Inventors: Nicholas Carruthers, Chandravadan Shah, Devin Swanson
  • Publication number: 20050049241
    Abstract: There are disclosed novel pyridyl piperazinyl ureas that are potent antagonists of vanilloid receptor, VR1, and are useful for the treatment and/or prevention of i) acute or chronic pain or itch; ii) inflammation; iii) gastrointestinal and urinary tract disorders; and iv) tracheobronchial and diaphragmatic dysfunction in humans.
    Type: Application
    Filed: August 4, 2004
    Publication date: March 3, 2005
    Inventors: Nicholas Carruthers, Chandravadan Shah, Devin Swanson